Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 291-299

  Liu, Zhendong ^a   Zhao, Yingxin ^a   Wei, Fang ^b   Ye, Lin ^c   Lu, Fanghong ^a   Zhang, Hua ^a   Diao, Yutao ^a   Song, Hongbin ^a   Qi, Zaiwen ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Angiotensin II receptor blockers; Anti inflammation; Atherosclerosis; Hypertension; Statin; Synergistic effect

Indexed keywords

ANGIOTENSIN II RECEPTOR BLOCKERS; ANTI-INFLAMMATION; ATHEROSCLEROSIS; HYPERTENSION; STATIN; SYNERGISTIC EFFECT;

ADULT; AGED; BENZIMIDAZOLES; BENZOATES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PYRIMIDINES; SULFONAMIDES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84893840154     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.004     Document Type: Article

References (35)

1. Ross R. Atherosclerosis: an inflammatory disease. NEngl J Med 1999, 340:115-126.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Hanssom G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91:281-291.
4. Magen E., Feldman A., Cohen Z., et al. Circulating endothelial progenitor cells, Th1/Th2/Th17-related cytokines, and endothelial dysfunction in resistant hypertension. Am J Med Sci 2010, 339:117-122.
5. Methe H., Brunner S., Wiegand D., Nabauer M., Koglin J., Edelman E.R. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. JAm Coll Cardiol 2005, 45:1939-1945.
6. Liu Z.D., Wang L., Lu F.H., et al. Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency in the peripheral circulation of patients with carotid artery plaque. Inflamm Res 2012, 61:1155-1165.
7. Xie J.J., Wang J., Tang T.T., et al. The Th17/Treg functional imbalance during atherogenesis in ApoE-/- miec. Cytokine 2010, 49:185-193.
8. Zhang J., Hua G., Zhang X., Tong R., Du X., Li Z. Regulatory T cells/T-helper cell 17 functional imbalance in uraemic patients on maintenance haemodialysis: a pivotal link between microinflammation and adverse cardiovascular events. Nephrololgy 2010, 15:33-41.
9. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
10. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
11. Cheng X., Yu X., Ding Y.J., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin immunol 2008, 127:89-97.
12. Li Q., Wang Y., Chen K., et al. The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome. Biochem Biophys Res Commun 2010, 394:836-842.
13. Nataraj C., Oliverio M.I., Mannon R.B., et al. Angiotensin II regulates cellular immune response through a calcineurin-dependent pathway. JClin Invest 1999, 104:1693-1701.
14. Shao J., Nangaku M., Miyata T., et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003, 42:31-38.
15. Madhur M.S., Lob H.E., McCann L.A., et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010, 55:500-507.
16. Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110:1103-1107.
17. Martinez-Martin F.J., Rodriguez-Rosas H., Lopez-Fernandez J., Soriano-Perera P., Pedrianes-Martin P., Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS Study. JHum Hypertens 2010, 25:346-353.
18. Manabe S., Okura T., Watanabe S., Fukuoka T., Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. JCardiovasc Pharmacol 2005, 46:735-739.
19. Ishii H., Tsukada T., Yoshida M. Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse vave velocity independent of its blood pressure lowering effects in type 2 diabetes patients. Intern Med 2008, 47:2013-2018.
20. Rajagopalan S., Zannad F., Radauceanu A., et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007, 100:222-226.
21. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:III39-III43.
22. Landsberger M., Wolff B., Jantzen F., et al. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cell. Atherosclerosis 2007, 190:43-52.
23. Ascer E., Bertolami M.C., Venturinelli M.L., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004, 177:161-166.
24. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
25. Chambless L.E., Folsam A.R., Davis V., et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2002, 155:38-47.
26. Sramek A., Bosch J.G., Reiber J.H., et al. Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000, 35:699-706.
27. Rahman S.T., Lauten W.B., Khan Q.A., et al. Effects of eprosartan versus hypdrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (rennin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 2002, 89:686-690.
28. Liu Z., Lu F., Pan H., et al. Correlation of peripheral Th17 cells and Th17-associated cytokines to the severity of carotid artery plaque and its clinical implication. Atherosclerosis 2012, 221:232-241.
29. Ceriello A., Assaloni R., Da Ros R., et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidiative stress, and in inflammation in type 2 diabetic patients. Circulation 2005, 111:2518-2524.
30. Hernández-Presa M., Bustos C., Ortego M., et al. Angiotensin converting enzyme inhibition prevents arterial NF-κB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997, 95:1532-1541.
31. Riaz A.A., Wang Y., Schramm R., et al. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J 2004, 18:881-883.
32. Long M., Park S.G., Strickland I., Hayden M.S., Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009, 31:921-931.
33. Romio M., Reinbeck B., Bongardt S., Hüls S., Burghoff S., Schrader J. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am J Physiol Cell Physiol 2011, 301(2):C530-C539.
34. Schuster M., Glauben R., Plaza-Sirvent C., et al. IκB(NS) protein mediates regulatory T cell development via induction of the Foxp3 transcription factor. Immunity 2012, 37(6):998-1008.
35. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapototic gene expression by RelA(p65) NF-κB. Mol Cell 2004, 13:853-865.